Novel melanoma antigen peptide and uses thereof

The invention relates to peptides derived from the MELOE antigen for therapeutic vaccination against cancer. A phase I clinical trial for ex-vivo therapy of melonama is ongoing.

Keywords: MELOE, antigen, cancer, melanoma, TIL, vaccination
Patent Application number: International Procedure (PCT) - 22 Mai 2012 - PCT/IB2012/001310
Inventors:
ROGEL Anne,LANG François,BOBINET Mathilde

Reference:

BIO12113-T1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 22-05-2012
Rare disease: No
Second indication: No

You might also be interested in